BCL2L1 and neoplasm: It appears reasonable to speculate that combining the systemic administration of Bcl-xL AS oligonucleotides with a localised treatment approach such as IR restricted to the tumour site could circumvent or at least minimise anticipated dose-limiting haematological side effects without negative impact on its sensitisation effect on tumor cells.